Allergy Therapeutics (AGY.L)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of £10,000 in Allergy Therapeutics, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Allergy Therapeutics (AGY.L) has returned -6.36% so far this year and 63.49% over the past 12 months.

Based on dividend-adjusted daily data since Jun 19, 2023, AGY.L's average daily return is +0.52%, while the average monthly return is +9.92%. At this rate, your investment would double in approximately 0.6 years.

Historically, 62% of months were positive and 38% were negative. The best month was Jul 2023 with a return of +181.9%, while the worst month was Sep 2023 at -49.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.

On a daily basis, AGY.L closed higher 40% of trading days. The best single day was Sep 27, 2023 with a return of +125.6%, while the worst single day was Sep 25, 2023 at -54.0%.

Allergy Therapeutics has an annualized alpha of 251.26%, beta of -0.05, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since June 20, 2023.

• This stock captured 813.19% of S&P 500 Index gains and 226.45% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• Beta of -0.05 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AGY.L ranks 77 for risk / return — better than 77% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Allergy Therapeutics (AGY.L) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Allergy Therapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Allergy Therapeutics was 68.03%, occurring on Sep 25, 2023. Recovery took 149 trading sessions.

The current Allergy Therapeutics drawdown is 14.88%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Allergy Therapeutics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Allergy Therapeutics is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.